Current stock price

Investor Relations

GCANRx is a publicly traded biotechnology company led by an experienced team of executives and scientists. The company is focused on the the development and commercialization of innovative Cannabinoid delivery systems.

Discover More
OCT 07, 2022

GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders

Read More
Dec 16, 2021

GCANRx Strategic Advisor Dr. Adi Aran to be Interviewed by Dr. Sanjay Gupta on CNN Cannabis Special

Read More
Dec 02, 2021

GCANRx Appoints Renowned Cannabinoid Researcher Dr. Adi Aran as Strategic Advisor

Read More
Show all News

Corporate Presentation

See our latest corporate presentation.

View presentation

Stock Information

See our current stock performance.

View stock information
Aitan Zacharin

Aitan Zacharin

CEO, Director

Mark Radom

Mark Radom

VP, General Counsel

David Tavor

David Tavor

Director, Board of Directors

Hock S. Tan

Hock S. Tan, PhD

Chairman, Scientific Advisory Board

More about our management

SEC Filings

NOV 21, 2022

Form PRE 14A

PDF HTML
Show all SEC Filings

FAQ

What is the ticker symbol for GCANRx?

Shares of GCANRx are traded on the OTC Markets under the ticker symbol GCAN.

Where is GCANRx’s corporate headquarters?

GCANRx is based out of Baltimore, MD.

When does GCANRx’s fiscal year end?

December 31.

Who is GCANRx’s transfer agent?

Pacific Stock Transfer. 6725 Via Austi Pkwy, Suite 300 Las Vegas, NV 89119. (800) 785-7782. info@pacificstocktransfer.com

Who is GCANRx’s auditor?

Michael T. Studer CPA P.C. 111 West Sunrise Highway, Second Floor East Freeport, NY 11520, United State

What is GCANRx's CUSIP number?

391657103

What is GCANRx's CIK Number?

0001695473

What is GCANRx's SIC and Classification?

2834; Pharmaceutical Preparations

What is GCANRx's O/S and Float?

As of October 26, 2018 the outstanding shares are 30,846,492 and the float is approximately 13,426,759

Sign up for email alerts

Stay up to date on the latest news.